Breakthrough in Early Cancer Detection: How a Fresh Blood Test Could Save Millions
Cancer remains one of the most formidable health challenges of our time, with early detection often making the difference between life and death. A groundbreaking partnership between Evexia Diagnostics and Cancer Check Labs is now poised to transform how we screen for cancer—before symptoms even appear. Their collaboration introduces a first-of-its-kind blood test capable of detecting over 200 types of solid tumor cancers as early as Stage 0, when survival rates can exceed 99%.
What sets this test apart? Unlike traditional screening methods that rely on fragmented genetic signals or biomarkers, this innovation isolates whole circulating tumor cells (CTCs) from the bloodstream, allowing board-certified pathologists to examine them under a microscope using gold-standard techniques. The result isn’t just a probability score—it’s a physician-grade pathology report, offering unprecedented clarity in early cancer detection.
How the CancerCheck Test Works: A Closer Look
The Science Behind Circulating Tumor Cells (CTCs)
Circulating tumor cells (CTCs) are malignant cells that break away from a solid tumor and enter the bloodstream. Their presence is a direct indicator of active cancer—not just genetic predisposition or risk. This distinction is critical. While other multi-cancer early detection (MCED) tests analyze fragments of DNA, proteins, or metabolites, the CancerCheck test captures whole, intact CTCs, providing a more complete and reliable picture of cancer activity.
Here’s how the process works:
- Blood Draw: A standard blood sample is collected, similar to routine lab work.
- CTC Isolation: Using proprietary filtration technology, the test extracts and isolates whole CTCs from the blood.
- Slide Preparation: Potential CTCs are affixed to a slide and stained using gold-standard histology and immunohistochemistry methods.
- Pathologist Review: An independent, board-certified pathologist examines the slides under a microscope, applying the same rigorous standards used in tissue biopsies.
- Pathology Report: The result is a detailed, physician-grade report that confirms the presence or absence of cancer cells.
Why Whole CTCs Matter
Most existing cancer screening tests rely on indirect signals, such as circulating tumor DNA (ctDNA) or biomarkers, which can produce false positives or negatives. In contrast, CTCs are living, intact cells that provide direct evidence of cancer. This approach eliminates much of the guesswork associated with other methods, offering a higher degree of specificity and clinical confidence.
As Cancer Check Labs explains, “CTCs are not just fragments of genetic material—they are whole cells that can be examined, stained, and verified by a pathologist. This is the same level of scrutiny applied in a traditional tissue biopsy, but without the invasiveness.”
The Advantages of Early Detection with CancerCheck
1. Detection as Early as Stage 0
Cancer is most treatable when caught early. The CancerCheck test is designed to detect solid tumor cancers at Stage 0, a phase where the disease is localized and has not yet spread. At this stage, survival rates for many cancers can exceed 99%, compared to significantly lower rates for later-stage diagnoses. For example, the five-year survival rate for Stage 0 breast cancer is nearly 100%, while the rate for Stage IV drops to around 22%.
2. Comprehensive Cancer Coverage
The test screens for over 200 types and subtypes of solid tumor cancers, which account for more than 90% of all cancer cases. This includes common cancers like breast, lung, colorectal, and prostate, as well as rarer forms that often lack dedicated screening tools. Because all solid tumors shed CTCs, the test is not limited to specific cancer types, making it a universal screening tool for early detection.
3. Board-Certified Pathology Report
One of the most significant differentiators of the CancerCheck test is its inclusion of a board-certified pathology report with every result. This means that every screening is reviewed by a qualified medical doctor, adding an extra layer of trust and reliability. Most other MCED tests provide a probability score or risk assessment, but CancerCheck delivers a definitive, pathologist-confirmed diagnosis—akin to what you’d receive from a tissue biopsy.
4. Minimally Invasive and Convenient
Traditional cancer screening methods, such as colonoscopies or mammograms, can be invasive, uncomfortable, and time-consuming. The CancerCheck test requires only a simple blood draw, making it a more accessible and patient-friendly option. This could encourage more people to undergo regular screening, particularly those who may avoid traditional methods due to fear or inconvenience.
Understanding the Limitations
While the CancerCheck test represents a major advancement in cancer screening, it is not a perfect solution. Like all medical tests, it has limitations that patients and providers should be aware of:
- Not a Diagnostic Tool: The test is not intended to diagnose, treat, cure, or prevent any disease. It should be used as a screening tool alongside established, evidence-based guidelines for cancer detection.
- False Positives and Negatives: No test is 100% accurate. There is a possibility of false positives (indicating cancer when none is present) or false negatives (missing cancer that is present).
- Limited to Solid Tumors: The test is designed to detect solid tumor cancers and may not identify blood cancers like leukemia or lymphoma.
- Not a Replacement for Traditional Screening: The test is not intended to replace existing screening methods, such as mammograms for breast cancer or colonoscopies for colorectal cancer. Instead, it should be used as a complementary tool to enhance early detection efforts.
As noted in the test’s official documentation, “CancerCheck is a screening tool that can provide valuable insights, but it should be used in conjunction with other diagnostic methods and under the guidance of a healthcare provider.”
The Partnership Behind the Innovation
The development and commercialization of the CancerCheck test are the result of a strategic partnership between Evexia Diagnostics, a leader in diagnostic testing solutions, and Cancer Check Labs, the company behind the proprietary CTC isolation technology. This collaboration aims to develop early, accurate cancer detection more accessible to patients worldwide.
Sumit Rai, Founder, CEO, and Chairman of Cancer Check Labs, emphasized the urgency of early detection in a recent statement: “One in three women and one in two men will be diagnosed with cancer in their lifetime. Early screening enabling early detection is the key to surviving cancer. Our partnership with Evexia Diagnostics brings us one step closer to making this a reality for millions of people.”
The partnership leverages Evexia Diagnostics’ expertise in diagnostic testing infrastructure and Cancer Check Labs’ cutting-edge technology to scale the availability of the CancerCheck test. This collaboration is expected to accelerate the adoption of the test in clinical settings, making it a standard part of routine cancer screening protocols.
Frequently Asked Questions
Who should consider taking the CancerCheck test?
The CancerCheck test is designed for individuals who are at average or elevated risk of developing cancer, particularly those with a family history of the disease or other risk factors. It is also suitable for individuals who may be hesitant to undergo more invasive screening methods, such as colonoscopies or biopsies. Yet, the test is not a replacement for traditional screening methods and should be used in conjunction with other diagnostic tools under the guidance of a healthcare provider.
How often should the test be taken?
The recommended frequency for taking the CancerCheck test has not yet been established by clinical guidelines. However, experts suggest that individuals at average risk may benefit from annual screening, while those at higher risk may require more frequent testing. Patients should consult their healthcare provider to determine the best screening schedule based on their personal risk factors.
Is the test covered by insurance?
As of April 2026, the CancerCheck test is relatively new to the market, and insurance coverage may vary. Patients are encouraged to check with their insurance provider to determine whether the test is covered under their plan. Some employers and healthcare providers may also offer the test as part of wellness programs or preventive care initiatives.
What happens if the test detects cancer?
If the CancerCheck test detects the presence of circulating tumor cells, the next step is to consult with a healthcare provider for further evaluation. This may include additional diagnostic tests, such as imaging studies or biopsies, to confirm the diagnosis and determine the stage and location of the cancer. Early detection provides the best opportunity for successful treatment, so prompt follow-up is critical.
How does the CancerCheck test compare to other MCED tests?
The CancerCheck test stands out from other multi-cancer early detection (MCED) tests due to its use of whole circulating tumor cells (CTCs) and the inclusion of a board-certified pathology report. Most other MCED tests rely on indirect signals, such as ctDNA or biomarkers, which can lead to less accurate results. The CancerCheck test’s use of gold-standard pathology methods provides a higher level of confidence in the results, making it a unique and valuable tool in the fight against cancer.
Key Takeaways
- Early Detection Saves Lives: The CancerCheck test can detect over 200 types of solid tumor cancers as early as Stage 0, when survival rates are highest.
- Whole CTCs for Greater Accuracy: Unlike other tests that analyze fragmented genetic material, CancerCheck isolates whole circulating tumor cells, providing direct evidence of cancer activity.
- Board-Certified Pathology Report: Every test result is reviewed by a board-certified pathologist, ensuring a high level of accuracy and reliability.
- Minimally Invasive: The test requires only a simple blood draw, making it a more accessible and patient-friendly option compared to traditional screening methods.
- Not a Replacement for Traditional Screening: The test should be used alongside established screening methods and under the guidance of a healthcare provider.
- Partnership for Scalability: The collaboration between Evexia Diagnostics and Cancer Check Labs aims to make the test widely available, accelerating its adoption in clinical settings.
The Future of Cancer Screening
The partnership between Evexia Diagnostics and Cancer Check Labs marks a significant milestone in the fight against cancer. By combining cutting-edge technology with gold-standard pathology methods, the CancerCheck test offers a new frontier in early detection, one that could save countless lives by catching cancer before it becomes life-threatening.
As research and technology continue to advance, the hope is that tests like CancerCheck will become a routine part of preventive healthcare, empowering individuals to take control of their health and detect cancer at its earliest, most treatable stages. While the test is not a panacea, it represents a powerful tool in the ongoing effort to reduce the global burden of cancer.
For those interested in learning more or exploring whether the CancerCheck test is right for them, visit Cancer Check Labs or consult with a healthcare provider to discuss the best screening options based on individual risk factors.